PLCD3

Across TCGA pan-cancer cohorts, PLCD3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLCD3 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PLCD3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PLCD3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

LSCC, PDAC, and GBM are the cancer types where PLCD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.900	1.000	.016	9	view →
PDAC	OS	Quartile	II,III,IV	0.713	0.384	.005	9	view →
GBM	OS	Tertile	All	0.431	0.625	.021	9	view →
CCRCC	OS	Median	All	0.761	1.000	.013	8	view →
LUAD	OS	Median	All	0.789	0.901	.024	2	view →
HNSC	DFS	Median	IV	1.000	0.927	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLCD3–LSCC (OS)

Open the LSCC breakdown →